Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
- PMID: 38385196
- PMCID: PMC11016470
- DOI: 10.3350/cmh.2024.0116
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
Keywords: Complement system proteins; Drug repositioning; Hepatocellular carcinoma; Liver diseases; Mendelian randomization.
Conflict of interest statement
J.D.Y. provides a consulting service for AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences, and Gilead Sciences. M.S.R-Z. and N.K. declare no conflict of interest.
Comment on
-
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.Clin Mol Hepatol. 2024 Jan;30(1):80-97. doi: 10.3350/cmh.2023.0343. Epub 2023 Dec 7. Clin Mol Hepatol. 2024. PMID: 38061333 Free PMC article.
References
-
- Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–1991. - PubMed
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
